Invesco NASDAQ Biotech UCITS ETF Acc
Product description
The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the total return performance of the NASDAQ Biotechnology Index (the “Reference Index”), less the impact of fees.
The Reference Index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The Reference Index is rebalanced quarterly and reviewed annually in December.
The fund aims to achieve its objective by holding a basket of equities, which typically delivers most of the fund’s return but ordinarily would not be the same as those in the Reference Index. The fund will also use unfunded swaps, which are contracts whereby one or more approved counterparties agrees to exchange with the fund any difference between the returns of the Reference Index and the basket of equities held. The aim is to achieve a closer and more consistent performance relative to the Reference Index than would generally be possible through physical replication alone.
This ETF is passively managed.
Key information
Bloomberg ticker | SBIO LN |
ISIN | IE00BQ70R696 |
Benchmark BBG ticker | XNBI |
Management fee | 0.40% |
Swap fee | 0.00% |
NAV (17 Apr 2024) | $42.33 |
AUM | $567,207,045 |
Base currency | USD |
Replication method | Synthetic |
Summary Risk Indicator (SRI) | 5 |
Umbrella AUM (17 Apr 2024) | $45,002,744,927 |
ESG Profile
(Index 17 Apr 2024)
ESG Rating (AAA-CCC) | A |
Quality Score (0-10) | 6.19 |
Carbon Intensity | 24.28 |
Source: MSCI ESG Research. For more information on the ESG profile, see the ESG section on this product page. Carbon intensity is the weighted average carbon intensity (Tons CO2e/$million sales).
Costs may increase or decrease as result of currency and exchange rate fluctuations. Consult the legal documents for further information on costs.
The investment concerns the acquisition of units in a fund and not in a given underlying asset.
Nasdaq®, NASDAQ Stock Market® are registered trademarks of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporations”) and are licensed for use by Invesco UK Services Limited. The Product(s) have not been passed on by the Corporations as to their legality or suitability. The Product(s) are not issued, endorsed, sold, or promoted by the Corporations. The Corporations make no warranties and bear no liability with respect to the product(s).
The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.
The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.
ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.
The risk / reward profile classifies the fund by an indicator representing the levels from the lowest (1) to the highest (7). For more information see the KID/KIID.